These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38801362)

  • 1. [Growth Hormone treatment in children with Growth Hormone deficiency, idiopathic short stature, SHOX gene mutation, small for gestational age and Turner syndrome].
    Griffero González M; González Navarrete D; Tolosa Navarro F; López Cuevas P; Rodríguez Convertino F; Román Reyes R
    Andes Pediatr; 2024 Apr; 95(2):151-158. PubMed ID: 38801362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of growth hormone treatment on children with idiopathic short stature (ISS), idiopathic growth hormone deficiency (IGHD), small for gestational age (SGA) and Turner syndrome (TS) in a tertiary care center.
    Al Shaikh A; Daftardar H; Alghamdi AA; Jamjoom M; Awidah S; Ahmed ME; Soliman AT
    Acta Biomed; 2020 Mar; 91(1):29-40. PubMed ID: 32191651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone age progression during the first year of growth hormone therapy in pre-pubertal children with idiopathic growth hormone deficiency, Turner syndrome or idiopathic short stature, and in short children born small for gestational age: analysis of data from KIGS (Pfizer International Growth Database).
    Darendeliler F; Ranke MB; Bakker B; Lindberg A; Cowell CT; Albertsson-Wikland K; Reiter EO; Price DA
    Horm Res; 2005; 63(1):40-7. PubMed ID: 15627781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Height gains in response to growth hormone treatment to final height are similar in patients with SHOX deficiency and Turner syndrome.
    Blum WF; Cao D; Hesse V; Fricke-Otto S; Ross JL; Jones C; Quigley CA; Binder G
    Horm Res; 2009; 71(3):167-72. PubMed ID: 19188742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Observed and predicted total pubertal growth during treatment with growth hormone in adolescents with idiopathic growth hormone deficiency, Turner syndrome, short stature, born small for gestational age and idiopathic short stature: KIGS analysis and review.
    Ranke MB; Lindberg A
    Horm Res Paediatr; 2011; 75(6):423-32. PubMed ID: 21358173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation.
    Takeda A; Cooper K; Bird A; Baxter L; Frampton GK; Gospodarevskaya E; Welch K; Bryant J
    Health Technol Assess; 2010 Sep; 14(42):1-209, iii-iv. PubMed ID: 20849734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of SHOX haploinsufficiency among short statured children.
    Marstrand-Joergensen MR; Jensen RB; Aksglaede L; Duno M; Juul A
    Pediatr Res; 2017 Feb; 81(2):335-341. PubMed ID: 27814343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GH treatment to final height produces similar height gains in patients with SHOX deficiency and Turner syndrome: results of a multicenter trial.
    Blum WF; Ross JL; Zimmermann AG; Quigley CA; Child CJ; Kalifa G; Deal C; Drop SL; Rappold G; Cutler GB
    J Clin Endocrinol Metab; 2013 Aug; 98(8):E1383-92. PubMed ID: 23720786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mortality in Children Receiving Growth Hormone Treatment of Growth Disorders: Data From the Genetics and Neuroendocrinology of Short Stature International Study.
    Quigley CA; Child CJ; Zimmermann AG; Rosenfeld RG; Robison LL; Blum WF
    J Clin Endocrinol Metab; 2017 Sep; 102(9):3195-3205. PubMed ID: 28575299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of growth hormone treatment in pediatric patients with idiopathic short stature.
    Quigley CA; Gill AM; Crowe BJ; Robling K; Chipman JJ; Rose SR; Ross JL; Cassorla FG; Wolka AM; Wit JM; Rekers-Mombarg LT; Cutler GB
    J Clin Endocrinol Metab; 2005 Sep; 90(9):5188-96. PubMed ID: 15899952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of growth hormone treatment in children with short stature: the Italian cohort of the GeNeSIS clinical study.
    Cappa M; Iughetti L; Loche S; Maghnie M; Vottero A;
    J Endocrinol Invest; 2016 Jun; 39(6):667-77. PubMed ID: 27223400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is the growth outcome of children with idiopathic short stature and isolated growth hormone deficiency following treatment with growth hormone and a luteinizing hormone-releasing hormone agonist superior to that obtained by GH alone?
    Colmenares A; González L; Gunczler P; Lanes R
    J Pediatr Endocrinol Metab; 2012; 25(7-8):651-7. PubMed ID: 23155689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth response to growth hormone (GH) treatment in children with GH deficiency (GHD) and those with idiopathic short stature (ISS) based on their pretreatment insulin-like growth factor 1 (IGFI) levels and at diagnosis and IGFI increment on treatment.
    Soliman A; Rogol AD; Elsiddig S; Khalil A; Alaaraj N; Alyafie F; Ahmed H; Elawwa A
    J Pediatr Endocrinol Metab; 2021 Oct; 34(10):1263-1271. PubMed ID: 34291621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Responses to growth hormone (GH) therapy in short children with normal GH secretion and no bone age delay: an analysis of potential factors affecting their response to rhGH therapy. A controlled study.
    Soliman AT; Elawwa A; Itani M; Jour C; De Sanctis V
    Acta Biomed; 2019 Sep; 90(8-S):43-51. PubMed ID: 31544806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth hormone is effective in treatment of short stature associated with short stature homeobox-containing gene deficiency: Two-year results of a randomized, controlled, multicenter trial.
    Blum WF; Crowe BJ; Quigley CA; Jung H; Cao D; Ross JL; Braun L; Rappold G;
    J Clin Endocrinol Metab; 2007 Jan; 92(1):219-28. PubMed ID: 17047016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-life GH dosing patterns in children with GHD, TS or born SGA: a report from the NordiNet® International Outcome Study.
    Blankenstein O; Snajderova M; Blair J; Pournara E; Pedersen BT; Petit IO
    Eur J Endocrinol; 2017 Aug; 177(2):145-155. PubMed ID: 28522645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of short stature caused by SHOX defects and therapeutic effect of recombinant human growth hormone.
    Binder G; Schwarze CP; Ranke MB
    J Clin Endocrinol Metab; 2000 Jan; 85(1):245-9. PubMed ID: 10634394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The growth response to GH treatment is greater in patients with SHOX enhancer deletions compared to SHOX defects.
    Donze SH; Meijer CR; Kant SG; Zandwijken GR; van der Hout AH; van Spaendonk RM; van den Ouweland AM; Wit JM; Losekoot M; Oostdijk W
    Eur J Endocrinol; 2015 Nov; 173(5):611-21. PubMed ID: 26264720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-for-gestational-age children.
    Binder G; Baur F; Schweizer R; Ranke MB
    J Clin Endocrinol Metab; 2006 Feb; 91(2):659-64. PubMed ID: 16291706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Growth Hormone Results in Different Diagnosis and Trend Over 10 Year of Follow-up: A Single Center Experience.
    Aycan Z; Araslı Yılmaz A; Yel S; Savaş-Erdeve Ş; Çetinkaya S
    J Clin Res Pediatr Endocrinol; 2021 Aug; 13(3):332-341. PubMed ID: 33749217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.